Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $17.00 Consensus Price Target from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has received a consensus rating of “Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $17.00.

Several equities analysts have recently weighed in on the stock. Leerink Partners started coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price for the company. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Wedbush began coverage on Voyager Therapeutics in a report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price target for the company. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th.

Voyager Therapeutics Trading Down 1.7 %

Voyager Therapeutics stock opened at $5.69 on Tuesday. The business’s 50 day simple moving average is $6.54 and its 200 day simple moving average is $7.12. Voyager Therapeutics has a 12 month low of $5.19 and a 12 month high of $11.72. The company has a market cap of $310.82 million, a price-to-earnings ratio of 8.01 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter in the prior year, the firm earned ($0.59) EPS. As a group, equities research analysts forecast that Voyager Therapeutics will post -0.89 earnings per share for the current fiscal year.

Insider Activity

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its position in Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after buying an additional 4,098 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Voyager Therapeutics in the 3rd quarter worth approximately $74,000. SG Americas Securities LLC purchased a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at $85,000. Victory Capital Management Inc. grew its holdings in shares of Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after purchasing an additional 1,630 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new position in Voyager Therapeutics in the 2nd quarter worth $128,000. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.